VYNE Q4 2022 Earnings Report
Key Takeaways
VYNE Therapeutics reported its Q4 and year-end 2022 financial results, highlighting the progress of its VYN201 and VYN202 programs and the ongoing Phase 1b trial for vitiligo.
VYNE is progressing in developing therapies for immuno-inflammatory conditions using its InhiBETâ„¢ platform.
Positive preliminary safety and tolerability data were announced from the Phase 1a/b trial of VYN201.
Patient enrollment is complete for the first dose cohort in the Phase 1b portion of the VYN201 trial, with enrollment ongoing for the remaining cohorts.
VYNE anticipates initial efficacy results from the Phase 1b trial in mid-2023.
VYNE
VYNE
Forward Guidance
VYNE anticipates that its cash and cash equivalents and restricted cash as of December 31, 2022, will be sufficient to fund its operations into the fourth quarter of 2023.